Nektar Therapeutics Announces New Data From Phase 2b Studies In Dermatitis And Alopecia Treatment Rezpegaldesleukin Has Been Accepted For Two Oral Presentations At The 2026 AAD Annual Meeting, March 27-31

Nektar Therapeutics has announced new data from Phase 2b studies for its treatment Rezpegaldesleukin, a first-in-class regulatory T cell stimulator aimed at autoimmune disorders and chronic inflammatory conditions. The data has been accepted for two oral presentations at the 2026 AAD Annual Meeting scheduled for March 27-31. Rezpegaldesleukin targets the IL-2 receptor complex to stimulate Treg cell proliferation while avoiding stimulation of cytotoxic T cells.